Dash to bring pharmacology background to drive product development and design services for SilcsBio

July 8, 2022, Baltimore, MD – SilcsBio, a technology company that develops and markets software and services for structure-based drug design, today announced the hiring of RC Dash, an accomplished pharmacologist with significant research experience in drug design, as Applications Scientist.

In his new role, Dash will provide expertise in rational hit identification, hit-to-lead optimization, molecular modeling and compound screening.

Dash earned his PhD at Poona College of Pharmacy, Pune, India, concentrating on the design, synthesis and pharmacological evaluation of new chemical entities as potential atypical antipsychotic agents.

In his most recent position, Dash worked as a postdoctoral researcher at the University of Connecticut, focusing on the identification of new ligands as TLS and Hh signaling inhibitors. He also worked on understanding the molecular recognition of complex biological systems at the atomic level using computational methods.

As part of his academic and research background, Dash’s experience also includes computational study including rational drug design, small molecule synthesis and evaluation.

“With SilcsBio’s continued growth, we knew we needed someone with strong medicinal chemistry knowledge,” said Ken Malone, CEO of SilcsBio. “RC brings that area of expertise and gives us a way to accelerate further our product development and customer service efforts.”

About SilcsBio:
SilcsBio, LLC offers the SILCS platform technology that advances computational drug design applications through detailed protein mapping that accounts for flexibility and solvation and enables highly efficient ligand binding evaluation, virtual screening, and more. SilcsBio software and services span from target protein mapping and analysis through lead optimization and offers key insights for biological therapeutic formulations. The proprietary software unlocks hidden binding hotspots of target proteins and reveals the preferred ligand chemistries at those sites to rapidly guide the drug design process. SilcsBio most recently announced a partnership with Aikido Pharmaceuticals. Learn more: www.silcsbio.com

Media Contact:
Ken Berlack